Navigation Links
Neurobiological Technologies Sets Date for Third Quarter Financial Results
Date:5/8/2008

EMERYVILLE, Calif., May 8 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its third quarter 2008 financial results, for the quarter ended March 31, 2008, on May 12, 2008 and host a conference call on May 13, 2008.

Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Matthew M. Loar, Vice President and Chief Financial Officer. The details for the call are as follows:

-- Date: Tuesday, May 13, 2008

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 877-591-4953 U.S. / 719-325-4851 International

Web cast of call: A live web cast can be accessed online by going to:

http://investor.shareholder.com/ntii/events.cfm

The call will be archived and accessible at the same website for 90 days

Telephonic Replay: A playback of the conference call will be available

from 1:30 pm (ET) on May 13, 2008 to midnight on May 17, 2008. Reply

number:

888-203-1112 U.S. / 719-457-0820 International Pass code: 3838724

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug with multiple mechanisms of action that is specifically designed to double the time period that patients can be treated after the onset of a stroke. NTI also has the right to receive royalty payments from sales of Namenda(R) (memantine HCL), an approved drug marketed for Alzheimer's disease, and the right to receive payments from the development and marketing of XERECEPT(R) (corticorelin acetate injection), an investigational drug in Phase 3 clinical development for swelling associated with brain tumors. Additionally, NTI has rights to two compounds in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 23, 2017 China Biologic Products, Inc. (NASDAQ: ... plasma-based biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2016 Financial Highlights ... by 21.7% in RMB terms, or increased by 13.6% in ... same quarter of 2015. Gross profit increased ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... Services portfolio to include an array of biochemical analyses critical for Lead ... to drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism ...
(Date:2/23/2017)... 23, 2017  Imanis Life Sciences announced today ... oncolytic vaccinia viruses for virotherapy research. These viruses ... Genelux,s proprietary, vaccinia virus-based technology platform for research ... into a partnership with Genelux to offer researchers, ... for use in research," said Dr. Kah ...
(Date:2/23/2017)... Winston-Salem, NC (PRWEB) , ... February 23, 2017 , ... ... pleased to announce a new partnership with Compass Research . GGI's mission is ... gifting a vaccine to a child in need in honor of each clinical trial ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):